MX2012000414A - Derivados piridin-4-ilo. - Google Patents

Derivados piridin-4-ilo.

Info

Publication number
MX2012000414A
MX2012000414A MX2012000414A MX2012000414A MX2012000414A MX 2012000414 A MX2012000414 A MX 2012000414A MX 2012000414 A MX2012000414 A MX 2012000414A MX 2012000414 A MX2012000414 A MX 2012000414A MX 2012000414 A MX2012000414 A MX 2012000414A
Authority
MX
Mexico
Prior art keywords
sup
derivatives
pyridin
formula
preparation
Prior art date
Application number
MX2012000414A
Other languages
English (en)
Inventor
Beat Steiner
Boris Mathys
Claus Mueller
Oliver Nayler
Martin Bolli
Cyrille Lescop
Keith Morrison
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42734812&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2012000414(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Publication of MX2012000414A publication Critical patent/MX2012000414A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4

Abstract

La presente invención se relaciona con derivados piridina de fórmula (I) (ver fórmula (I)) en donde A, R1, R2, R3, y R4 son tal como se explica en la descripción, su preparación y su uso como compuestos farmacéuticamente activos. Estos compuestos actúan de manera particular como agentes inmuno-moduladores.
MX2012000414A 2009-07-16 2010-07-15 Derivados piridin-4-ilo. MX2012000414A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IB2009053089 2009-07-16
PCT/IB2010/053224 WO2011007324A1 (en) 2009-07-16 2010-07-15 Pyridin-4-yl derivatives

Publications (1)

Publication Number Publication Date
MX2012000414A true MX2012000414A (es) 2012-02-08

Family

ID=42734812

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012000414A MX2012000414A (es) 2009-07-16 2010-07-15 Derivados piridin-4-ilo.

Country Status (27)

Country Link
US (1) US8658675B2 (es)
EP (1) EP2454255B1 (es)
JP (1) JP5036923B1 (es)
KR (1) KR101409131B1 (es)
CN (1) CN102471328B (es)
AR (1) AR077413A1 (es)
AU (1) AU2010272219B2 (es)
BR (1) BR112012000763B8 (es)
CA (1) CA2767585C (es)
CY (1) CY1114759T1 (es)
DK (1) DK2454255T3 (es)
ES (1) ES2441845T3 (es)
HK (1) HK1170479A1 (es)
HR (1) HRP20140098T1 (es)
IL (1) IL217490A (es)
MA (1) MA33528B1 (es)
MX (1) MX2012000414A (es)
MY (1) MY153617A (es)
NZ (1) NZ598173A (es)
PL (1) PL2454255T3 (es)
PT (1) PT2454255E (es)
RU (1) RU2547098C2 (es)
SG (1) SG178042A1 (es)
SI (1) SI2454255T1 (es)
TW (1) TWI410421B (es)
WO (1) WO2011007324A1 (es)
ZA (1) ZA201201125B (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009002233A (es) * 2006-09-07 2009-03-16 Actelion Pharmaceuticals Ltd Derivados de piridin-4-il como agentes inmunomoduladores.
EP2125797B1 (en) 2007-03-16 2014-01-15 Actelion Pharmaceuticals Ltd. Amino- pyridine derivatives as s1p1 /edg1 receptor agonists
WO2009024905A1 (en) * 2007-08-17 2009-02-26 Actelion Pharmaceuticals Ltd Pyridine derivatives as s1p1/edg1 receptor modulators
TW200920746A (en) * 2007-11-01 2009-05-16 Actelion Pharmaceuticals Ltd Novel pyrimidine derivatives
US20110028448A1 (en) * 2008-03-06 2011-02-03 Martin Bolli Pyridine compounds
PL2252609T3 (pl) * 2008-03-07 2013-09-30 Idorsia Pharmaceuticals Ltd Pochodne pirydyn-2-ylu jako środki immunomodulujące
CA2715317A1 (en) 2008-03-07 2009-09-11 Actelion Pharmaceuticals Ltd Novel aminomethyl benzene derivatives
PT2665720E (pt) 2011-01-19 2015-09-16 Actelion Pharmaceuticals Ltd Derivados de 2-metoxi-piridin-4-ilo
MX2014014138A (es) * 2012-05-22 2015-02-24 Actelion Pharmaceuticals Ltd Procedimiento nuevo para la preparacion de acido 2-ciclopentil-6-metoxi-isonicotinico.
UA115357C2 (uk) 2013-03-15 2017-10-25 Ідорсія Фармасьютікалз Лтд Похідні піридин-4-ілу
EP3298008B1 (en) 2015-05-20 2019-11-20 Idorsia Pharmaceuticals Ltd Crystalline form of the compound (s)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propane-1,2-diol
EP3590929B1 (en) * 2017-02-28 2021-09-15 Medshine Discovery Inc. Spiro compound and use thereof
CN107445941A (zh) * 2017-08-14 2017-12-08 河南科技大学第附属医院 具有免疫抑制活性的三氮唑类化合物的制备方法及应用
CN107382965A (zh) * 2017-08-14 2017-11-24 河南科技大学第附属医院 具有抗肿瘤活性的新型s1p‑1受体激动剂药物分子的合成方法
CN107311994A (zh) * 2017-08-14 2017-11-03 淄博职业学院 一种s1p‑1受体激动剂药物分子的新型合成方法
US11014897B1 (en) 2018-10-16 2021-05-25 Celgene Corporation Solid forms comprising a thiazolidinone compound, compositions and methods of use thereof
US11186556B1 (en) 2018-10-16 2021-11-30 Celgene Corporation Salts of a thiazolidinone compound, solid forms, compositions and methods of use thereof
US11014940B1 (en) 2018-10-16 2021-05-25 Celgene Corporation Thiazolidinone and oxazolidinone compounds and formulations
US11013723B1 (en) 2018-10-16 2021-05-25 Celgene Corporation Solid forms of a thiazolidinone compound, compositions and methods of use thereof
CN109369620B (zh) * 2018-12-22 2020-04-14 山东大学 吡啶类化合物及其制备方法与抗胃癌应用
CA3156298A1 (en) 2019-10-31 2021-05-06 Laetitia POUZOL Combination of a cxcr7 antagonist with an s1p1 receptor modulator
WO2021148314A1 (en) 2020-01-20 2021-07-29 Idorsia Pharmaceuticals Ltd Accelerated elimination of (s)-3-{4-[5-(2-cyclopentyl-6-methoxy-pyridin-4-yl)-[1,2,4]oxadiazol-3-yl]-2-ethyl-6-methyl-phenoxy}-propane-1,2-diol
TW202139982A (zh) 2020-02-06 2021-11-01 日商田邊三菱製藥股份有限公司 肌痛性腦脊髓炎／慢性疲勞症候群治療劑
WO2021175223A1 (zh) * 2020-03-04 2021-09-10 南京明德新药研发有限公司 苯并2-氮杂螺[4.4]壬烷类化合物及其应用
CN116867771A (zh) * 2021-04-09 2023-10-10 南昌弘益药业有限公司 噁二唑取代的螺环类化合物及其应用
EP4212156A1 (en) 2022-01-13 2023-07-19 Abivax Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a s1p receptor modulator
WO2024056631A1 (en) 2022-09-14 2024-03-21 Idorsia Pharmaceuticals Ltd S1p 1 receptor modulators for use in the treatment of type 1 ifn mediated diseases

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3647809A (en) 1968-04-26 1972-03-07 Chinoin Gyogyszer Es Vegyeszet Certain pyridyl-1 2 4-oxadiazole derivatives
AU7686891A (en) 1990-04-05 1991-10-30 American National Red Cross, The A protein family related to immediate-early protein expressed by human endothelial cells during differentiation
CA2051494C (en) 1990-09-20 2006-03-14 Robert J. Dinerstein 1-aryl-3-pyridinyl-2-propene-1-ones as calcium uptake inhibitors
DE4429465A1 (de) 1994-08-19 1996-02-22 Bayer Ag Verfahren zur Herstellung von 2-Halogenpyridinaldehyden und neue 2-Halogenpyridinaldehyde
US6423508B1 (en) 1998-03-09 2002-07-23 Smithkline Beecham Corporation Polynucleotide sequences of human EDG-1c
DE19904389A1 (de) 1999-02-04 2000-08-10 Bayer Ag Verwendung von substituierten Isoxazolcarbonsäuren und Derivate und neue Stoffe
CZ2002599A3 (cs) 1999-08-19 2002-06-12 Nps Pharmaceuticals Inc. Heteropolycyklické sloučeniny a jejich pouľití jako antagonistů metabotropního receptoru glutamátu
RU2319701C2 (ru) 2001-02-21 2008-03-20 Астразенека Аб ГЕТЕРОПОЛИЦИКЛИЧЕСКОЕ СОЕДИНЕНИЕ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, ОБЛАДАЮЩАЯ АНТАГОНИСТИЧЕСКОЙ АКТИВНОСТЬЮ В ОТНОШЕНИИ МЕТАБОТРОПНЫХ ГЛЮТАМАТНЫХ РЕЦЕПТОРОВ mGluR ГРУППЫ I
ATE441654T1 (de) 2002-01-18 2009-09-15 Merck & Co Inc Edg-rezeptoragonisten
EP1575964B1 (en) 2002-01-18 2009-11-11 Merck & Co., Inc. N-(benzyl)aminoalkyl carboxylate, phosphinates, phosphonates and tetrazoles as edg receptor agonists
WO2003105771A2 (en) 2002-06-17 2003-12-24 Merck & Co., Inc. 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)azetidine-3-carboxylates and 1-((5-aryl-1,2,4-oxadiazol-3-yl)benzyl)pyrrolidine-3-carboxylates as edg receptor agonists
DE10237883A1 (de) 2002-08-19 2004-03-04 Merckle Gmbh Chem.-Pharm. Fabrik Substituierte Isoxazolderivate und ihre Verwendung in der Pharmazie
RU2331639C2 (ru) * 2002-08-23 2008-08-20 Райджел Фармасьютикалз, Инк. Пиридилзамещенные гетероциклы, пригодные для лечения или профилактики инфекции, вызванной вирусом гепатита с
WO2004035538A1 (en) 2002-10-15 2004-04-29 Merck & Co., Inc. Process for making azetidine-3-carboxylic acid
US20050004186A1 (en) 2002-12-20 2005-01-06 Pfizer Inc MEK inhibiting compounds
US20060252741A1 (en) * 2003-05-15 2006-11-09 Colandrea Vincent J 3-(2-amino-1-azacyclyl)-5-aryl-1,2,4-oxadiazoles as s1p receptor agonists
WO2005014525A2 (en) 2003-08-12 2005-02-17 Mitsubishi Pharma Corporation Bi-aryl compound having immunosuppressive activity
CN1859908A (zh) * 2003-10-01 2006-11-08 默克公司 作为s1p受体激动剂的3,5－芳基、杂芳基或环烷基取代的－1,2,4－噁二唑类化合物
CN1894225A (zh) * 2003-12-17 2007-01-10 默克公司 作为鞘氨醇1－磷酸(内皮分化基因)受体激动剂的(3,4－二取代)丙酸酯
AU2005247110B2 (en) 2004-05-29 2010-08-26 7Tm Pharma A/S CRTH2 receptor ligands for medicinal uses
WO2006010379A1 (en) 2004-07-29 2006-02-02 Actelion Pharmaceuticals Ltd. Novel thiophene derivatives as immunosuppressive agents
EP1804793A4 (en) 2004-10-22 2010-03-31 Merck Sharp & Dohme 2- (ARYL) AZACYCLYLMETHYL-CARBOXYLATE, SULPHONATE, PHOSPHONATE, PHOSPHINATE AND HETEROCYCLES AS S1P RECEPTOR AGONISTS
KR101262400B1 (ko) 2004-12-13 2013-05-08 오노 야꾸힝 고교 가부시키가이샤 아미노카르복실산 유도체 및 그 의약 용도
KR101382733B1 (ko) 2005-03-23 2014-04-14 액테리온 파마슈티칼 리미티드 면역조절물질로서의 수첨 벤조(ｃ) 티오펜 유도체
CA2602478A1 (en) 2005-03-23 2006-09-28 Actelion Pharmaceuticals Ltd Novel thiophene derivatives
KR20070116645A (ko) 2005-03-23 2007-12-10 액테리온 파마슈티칼 리미티드 스핑고신-1-포스페이트-1 수용체 길항제로서의 신규한티오펜 유도체
BRPI0610514A2 (pt) 2005-04-05 2016-11-16 Pharmacopeia Inc composto, composição farmacêutica, e, método de tratamento de um distúrbio
CN101203512A (zh) 2005-04-22 2008-06-18 第一三共株式会社 杂环化合物
JP2008539195A (ja) 2005-04-26 2008-11-13 ノイロサーチ アクティーゼルスカブ 新規のオキサジアゾール誘導体及びそれらの医学的使用
BRPI0612028A2 (pt) 2005-06-08 2010-10-13 Novartis Ag oxadiazóis ou isodiazóis policìclicos e uso dos mesmos como ligantes de receptor s1p
WO2006135694A2 (en) 2005-06-10 2006-12-21 Acadia Pharmaceuticals Inc. Uii-modulating compounds and their use
KR20080024533A (ko) 2005-06-24 2008-03-18 액테리온 파마슈티칼 리미티드 신규한 티오펜 유도체
US20090054491A1 (en) 2005-06-28 2009-02-26 Astrazeneca Ab Use
AR057894A1 (es) 2005-11-23 2007-12-26 Actelion Pharmaceuticals Ltd Derivados de tiofeno
TWI404706B (zh) 2006-01-11 2013-08-11 Actelion Pharmaceuticals Ltd 新穎噻吩衍生物
EP1979345B1 (en) 2006-01-24 2009-11-04 Actelion Pharmaceuticals Ltd. Novel pyridine derivatives
GB0601744D0 (en) 2006-01-27 2006-03-08 Novartis Ag Organic compounds
CN101384566A (zh) 2006-02-21 2009-03-11 弗吉尼亚大学专利基金会 作为s1p受体激动剂的苯基-环烷基和苯基-杂环衍生物
EA200802058A1 (ru) 2006-05-09 2009-06-30 Пфайзер Продактс Инк. Производные циклоалкиламинокислот и их фармацевтические композиции
AR061841A1 (es) 2006-09-07 2008-09-24 Actelion Pharmaceuticals Ltd Derivados de tiofen-oxadiazoles, agonistas del receptor s1p1/edg1, composiciones farmaceuticas que los contienen y usos como agentes inmunomoduladores.
MX2009002233A (es) * 2006-09-07 2009-03-16 Actelion Pharmaceuticals Ltd Derivados de piridin-4-il como agentes inmunomoduladores.
KR101454937B1 (ko) 2006-09-08 2014-10-27 액테리온 파마슈티칼 리미티드 면역조절제로서 피리딘-3-일 유도체
US8044076B2 (en) 2006-09-21 2011-10-25 Actelion Pharmaceuticals Ltd. Phenyl derivatives and their use as immunomodulators
MX2009003129A (es) 2006-09-29 2009-04-06 Novartis Ag Derivados de oxadiazol con propiedades anti-inflamatorias e inmunosupresoras.
JP2008120794A (ja) 2006-10-16 2008-05-29 Daiichi Sankyo Co Ltd ヘテロ環化合物を含有する医薬組成物
US20110207704A1 (en) 2006-12-15 2011-08-25 Abbott Laboratories Novel Oxadiazole Compounds
SG177221A1 (en) 2006-12-15 2012-01-30 Abbott Lab Novel oxadiazole compounds
WO2008091967A1 (en) 2007-01-26 2008-07-31 Smithkline Beecham Corporation Chemical compounds
EP2125797B1 (en) 2007-03-16 2014-01-15 Actelion Pharmaceuticals Ltd. Amino- pyridine derivatives as s1p1 /edg1 receptor agonists
WO2009024905A1 (en) 2007-08-17 2009-02-26 Actelion Pharmaceuticals Ltd Pyridine derivatives as s1p1/edg1 receptor modulators
EA201070422A1 (ru) 2007-10-04 2010-12-30 Мерк Сероно С.А. Производные оксадиазола
JP5727223B2 (ja) 2007-10-04 2015-06-03 メルク セローノ ソシエテ アノニム オキサジアゾール・ジアリール化合物
TW200920746A (en) * 2007-11-01 2009-05-16 Actelion Pharmaceuticals Ltd Novel pyrimidine derivatives
JP2011503046A (ja) 2007-11-08 2011-01-27 ファイザー・インク シクロブチルカルボン酸誘導体
ES2403209T3 (es) 2007-12-10 2013-05-16 Actelion Pharmaceuticals Ltd. Derivados de tiofeno novedosos como agonistas de S1P1/EDG1
US20110028448A1 (en) 2008-03-06 2011-02-03 Martin Bolli Pyridine compounds
EP2262800A1 (en) 2008-03-06 2010-12-22 Actelion Pharmaceuticals Ltd. Novel pyrimidine-pyridine derivatives
CA2715317A1 (en) 2008-03-07 2009-09-11 Actelion Pharmaceuticals Ltd Novel aminomethyl benzene derivatives
PL2252609T3 (pl) 2008-03-07 2013-09-30 Idorsia Pharmaceuticals Ltd Pochodne pirydyn-2-ylu jako środki immunomodulujące
MY172105A (en) 2008-05-14 2019-11-14 Scripps Research Inst Novel modulators of sphingosine phosphate receptors
US20120101134A1 (en) 2009-06-26 2012-04-26 Glaxo Group Limited 5-membered heteroaryl derivatives used as sphingosine 1-phosphate receptor agonists

Also Published As

Publication number Publication date
SG178042A1 (en) 2012-03-29
JP5036923B1 (ja) 2012-09-26
JP2012533533A (ja) 2012-12-27
IL217490A0 (en) 2012-02-29
US20120108638A1 (en) 2012-05-03
BR112012000763B8 (pt) 2021-05-25
US8658675B2 (en) 2014-02-25
TWI410421B (zh) 2013-10-01
AR077413A1 (es) 2011-08-24
EP2454255B1 (en) 2013-11-06
SI2454255T1 (sl) 2014-01-31
RU2547098C2 (ru) 2015-04-10
RU2012105134A (ru) 2013-08-27
EP2454255A1 (en) 2012-05-23
CN102471328A (zh) 2012-05-23
DK2454255T3 (da) 2013-12-16
BR112012000763B1 (pt) 2021-02-09
AU2010272219B2 (en) 2015-02-26
KR101409131B1 (ko) 2014-06-17
WO2011007324A1 (en) 2011-01-20
CN102471328B (zh) 2015-04-01
PT2454255E (pt) 2014-01-14
MA33528B1 (fr) 2012-08-01
IL217490A (en) 2015-10-29
CA2767585A1 (en) 2011-01-20
PL2454255T3 (pl) 2014-04-30
CY1114759T1 (el) 2016-12-14
AU2010272219A1 (en) 2012-03-08
ZA201201125B (en) 2014-07-30
MY153617A (en) 2015-02-27
HK1170479A1 (en) 2013-03-01
KR20120069662A (ko) 2012-06-28
HRP20140098T1 (hr) 2014-03-14
CA2767585C (en) 2017-09-26
BR112012000763A2 (pt) 2018-03-13
ES2441845T3 (es) 2014-02-06
TW201107313A (en) 2011-03-01
NZ598173A (en) 2014-01-31

Similar Documents

Publication Publication Date Title
MX2012000414A (es) Derivados piridin-4-ilo.
MY149853A (en) Pyridin-4-yl derivatives as immunomodulating agents
MY150661A (en) Pyridin-3-yl derivatives as immunomodulating agents
MX2010005889A (es) Derivados de tiofeno como agonistas de s1p1/edg1.
MX2010004576A (es) Derivados de pirimidina novedosos.
ZA200807274B (en) Novel pyridine derivatives
MY183039A (en) Pyridin-2-yl derivatives as immunomodulating agents
MY153921A (en) Aminopyrazole derivatives
TW200942530A (en) Pyridine compounds
MX2010001881A (es) Derivados de piridina como moduladores del receptor s1p1/edg1.
TW200801000A (en) Spiroindolinone derivatives
MY147994A (en) Azabiphenylaminobenzoic acid derivatives as dhodh inhibitors
MY153985A (en) Aminotriazole derivatives as alx agonists
IN2012DN03337A (es)
MX342440B (es) Derivados fluorados de aminotriazol.
TW200942524A (en) Novel aminomethyl benzene derivatives
MX361618B (es) Formulaciones farmacéuticas que comprenden derivados de nitrocatecol y métodos para hacer las mismas.
IN2012DN03182A (es)
MX2010001338A (es) Derivados de pirimidina y piridina y su uso y composiciones farmaceuticas.
MY173573A (en) Pyridin-4-yl derivatives
UA102310C2 (ru) Гетероциклические сульфонамиды, их применение и фармацевтические композиции
MX2013006420A (es) Derivados de aminotriazol hidrolixado como agonistas del receptor de alx.
MX2012007896A (es) Derivados de piridino-piridinonas arilsulfonamidas, su preparacion y su uso en terapeutica.
MX2012002369A (es) Formas de anhidrato de un derivado de piridina.
MY163185A (en) 2-methoxy-pyridin-4-yl derivatives

Legal Events

Date Code Title Description
FG Grant or registration